Drug
Msb11022
Msb11022: highest development phase Phase 3, developed by Fresenius Kabi. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| MSB11022 NCT02660580 | Phase 3 | Psoriasis |
| 40 mg MSB11022 NCT04018599 | Phase 1 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Msb11022 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.